Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: [RETIRED]
- 27 March 2007
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 68 (13), 977-984
- https://doi.org/10.1212/01.wnl.0000258545.73854.cf
Abstract
The clinical and radiologic impact of developing neutralizing antibodies (NAbs) to interferon beta (IFNbeta) while on this therapy for multiple sclerosis (MS) is assessed. On the basis of Class II and III evidence, it is concluded that treatment of patients with MS with IFNbeta (Avonex, Betaseron, or Rebif) is associated with the production of NAbs (Level A). NAbs in the serum are probably associated with a reduction in the radiographic and clinical effectiveness of IFNbeta treatment (Level B). In addition, the rate of NAb production is probably less with IFNbeta-1a treatment than with IFNbeta-1b treatment, although the magnitude and persistence of this difference is difficult to determine (Level B). Finally, it is probable that there is a difference in seroprevalence due to variability in the dose of IFNbeta injected or in the frequency or route of its administration (Level B). Regardless of the explanation, it seems clear that IFNbeta-1a (as it is currently formulated for IM injection) is less immunogenic than the current IFNbeta preparations (either IFNbeta-1a or IFNbeta-1b) given multiple times per week subcutaneously (Level A). However, because NAbs disappear in some patients even with continued IFNbeta treatment (especially in patients with low titers), the persistence of this difference is difficult to determine (Level B). Although the finding of sustained high-titer NAbs (>100 to 200 NU/mL) is associated with a reduction in the therapeutic effects of IFNbeta on radiographic and clinical measures of MS disease activity, there is insufficient information on the utilization of NAb testing to provide specific recommendations regarding when to test, which test to use, how many tests are necessary, or which cutoff titer to apply (Level U).Keywords
This publication has 35 references indexed in Scilit:
- The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodiesJournal of Neuroimmunology, 2005
- Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosisNeurology, 2004
- A sensitive radioimmunoprecipitation assay for assessing the clinical relevance of antibodies to IFNJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice GuidelinesNeurology, 2002
- Review: Overlapping and Distinct Mechanisms Regulating IRF-3 and IRF-7 FunctionJournal of Interferon & Cytokine Research, 2002
- The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction UnitJournal of Interferon & Cytokine Research, 2001
- PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MSNeurology, 2001
- Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple SclerosisNew England Journal of Medicine, 2000
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Influence of the Carbohydrate Moiety on the Stability of GlycoproteinsBiochemistry, 1996